CCL2 News and Research

RSS

RhoGDI2 protein helps prevent bladder cancer metastasis to the lungs

The diagnosis of localized bladder cancer carries an 80 percent five-year survival rate, but once the cancer spreads, the survival rate at even three years is only 20 percent. A major study published today in the Journal of Clinical Investigation not only shows how bladder cancer metastasizes to the lungs but pinpoints a method for stopping this spread.

13 Mar 2012

Scientists decode unknown mechanism of imiquimod in tumour defense

A research team from the Institute for Cancer Research at the MedUni Vienna has decoded a previously unknown mechanism of the active ingredient imiquimod in tumour defense. They have been able to prove that imiquimod transforms plasmacytoid dendritic cells (pDCs) into "tumour-killers" which can fight the tumour independently from other immune cells. This discovery could be an important step on the way to a more efficient treatment for cancer.

20 Jan 2012

New trick of tumors

Tumors have an arsenal of tricks to help them sidestep the immune system. A study published on September 19 in the Journal of Experimental Medicine reveals a new trick—the ability to keep tumor-fighting T cells out by disabling a T cell-attracting protein within the tumor core.

20 Sep 2011

Researchers identify key molecule responsible for breast tumor metastasis

Researchers at Albert Einstein College of Medicine of Yeshiva University have identified a key player in the spread of breast cancer. The findings, published today in the online edition of Nature, identify a critical molecule that helps cancer spread beyond the primary tumor.

9 Jun 2011

Senescent melanoma cells express an inflammatory secretome

Malignant melanoma is a highly aggressive and notoriously chemoresistant form of cancer. In this paper, Ohanna et al. reveal that anti-melanoma drugs may, paradoxically, induce a senescence-associated secretory profile ("secretome") that can ultimately promote metastasis and contribute to melanoma relapse.

6 Jun 2011

PCF funds 14 new Creativity Awards for advanced prostate cancer research

The Prostate Cancer Foundation today announced that it has funded 14 new Creativity Awards for advanced prostate cancer research. These two-year awards are designed to support innovative research ideas that have the potential to achieve breakthroughs for improved prostate cancer diagnosis and treatment.

2 Jun 2011

ChemoCentryx presents CCX140 clinical data at EASD

ChemoCentryx, Inc., today announced that it reported positive preclinical and Phase I study results at the European Association for the Study of Diabetes (EASD). CCX140, a novel, orally bioavailable small molecule antagonist of the chemokine receptor CCR2, improved metabolic function while significantly reducing inflammatory macrophages found in adipose tissue in an animal model, and was well tolerated in Phase I clinical trials.

21 Sep 2010

Helper T cell's effect raises possibility of cellular therapy and vaccine development

A specific type of T helper cell awakens the immune system to the stealthy threat of cancer and triggers an attack of killer T cells custom-made to destroy the tumors, scientists from The University of Texas M. D. Anderson Cancer Center report in the early online edition of the journal Immunity.

30 Oct 2009

New understanding on how inflammatory disease causes fatigue

New animal research in the February 18 issue of The Journal of Neuroscience may indicate how certain diseases make people feel so tired and listless.

18 Feb 2009

Research could lead to new treatments for idiopathic pulmonary fibrosis

Scientists at the University of Michigan Medical School have identified biochemical signals that attract pathogenic cells to damaged lung tissue - one of the first steps in a chain of events leading to a lethal disease called idiopathic pulmonary fibrosis or IPF.

23 May 2006

Blocking a key molecule protects breast implants, permanent catheters, pacemakers and artificial joints from rejection and damage by the body

Blocking a key molecule protects breast implants, permanent catheters, pacemakers, artificial joints, glucose sensors for diabetics, and other biomaterials from rejection and damage by the body, according to a study published this month in The American Journal of Pathology.

20 Dec 2004